IL13RA2 _ IL13R Protein
- Known as:
- IL13RA2 _ IL13R Protein
- Catalog number:
- 10350-H03H
- Product Quantity:
- 200
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- IL13RA2 _ IL13R Protein
Related genes to: IL13RA2 _ IL13R Protein
- Gene:
- IL13RA2 NIH gene
- Name:
- interleukin 13 receptor subunit alpha 2
- Previous symbol:
- -
- Synonyms:
- IL-13R, IL13BP, CD213a2, CT19
- Chromosome:
- Xq23
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-26
- Date modifiied:
- 2015-12-11
Related products to: IL13RA2 _ IL13R Protein
Related articles to: IL13RA2 _ IL13R Protein
- Patients with advanced malignant adrenal tumors face poor prognoses with limited treatment options. Emerging data suggest that these rare tumors exhibit immunogenicity, potentially benefiting from intensified immunotherapy. - Source: PubMed
Publication date: 2026/07/06
Schultheiß ChristophBesemer BrendaWillscher EdithPaschold LisaMersceman TifannyTalpin AliceSerger ClaraZippelius AlfredBerruti AlfredoGrisanti SalvatoreMenke-van der Houven van Oordt Catharina WillemienBaudin EricLandwehr Laura-SophieCapdevila JaumeSubbiah VivekGranberg DanGedske Daugaard KirstenTriebig AlexandraGauduchon ThibaultDo Cao ChristineGarcia Marie-EveMagalhaes JoaoChêne LaurentBinder Mascha - The failure of therapy in muscle invasive bladder cancer (MIBC) is primarily attributed to tumor heterogeneity and therapy resistance. We propose a novel approach targeting interleukin-13 receptor subunit alpha 2 (IL-13Rα2), which is expressed on bladder cancer (BC) cells but absent in normal urothelial cells. We investigated the therapeutic effects of WPD101a immunotoxin (IL-13-DT390) on IL-13Rα2-expressing BC cells in relation to BC cell phenotype and functional characteristics in vitro using both 2-dimensional (2D) and 3-dimensional (3D) models. Cell phenotype and IL-13Rα2 expression were assessed using flow cytometry, immunofluorescence, and Western blot analysis. The biological effects of WPD101a were evaluated by measuring cell viability and proliferation using the MTT, sulforhodamine B (SRB), CellTiter-Glo and Live/Dead assays. Apoptosis was assessed using Annexin V/propidium iodide (PI) staining, and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis of genes expression. We found that the reference BC cell lines TCC-SUP, JMSU-1 and UM-UC-3 express IL-13Rα2 at various level in contrast to RT-4, HCV-29 and 5637 cells. Cells expressing IL-13Rα2 were sensitive to WPD101a at lower concentrations in the 2D model (0.1 ng/mL) compared to the 3D model (1.0 ng/mL). IL-13Rα2-negative cells remain resistant to the immunotoxin. WPD101a induces apoptosis in BC cells expressing IL-13Rα2 as confirmed by the presence of apoptotic cells, increase the proportion of cells in the subG1 phase, and by the effector , , and initiator , genes expression. This study confirmed receptor-dependent cytotoxic effects of WPD101a and the ability and specificity to inhibit growth and apoptosis induction in MIBC cells expressing IL-13Rα2. - Source: PubMed
Publication date: 2026/06/19
Klimczak AleksandraKrawczenko AgnieszkaStamnitz SandraBielawska-Pohl AleksandraPiotrowska PaulinaGrzelenska HannaWypychowska AleksandraKisielewicz AlicjaMielecki MarcinBorowski RadoslawOlejniczak MariuszPajak-Tarnacka Beata - Glioblastoma (GBM) is the most aggressive primary malignant brain tumor, and while chimeric antigen receptor-T (CAR-T) cell therapy has shown promise, its efficacy remains limited by antigen heterogeneity and immune escape. Here, we investigated the expression of B7 homolog 3 (B7-H3), epidermal growth factor receptor (EGFR), and interleukin-13 receptor alpha 2 (IL-13RA2) in GBM tissues and cell lines. Although all three antigens were highly expressed, sustained exposure to B7-H3 CAR-T cells led to significant B7-H3 downregulation but concurrent EGFR upregulation, revealing a potential immune escape mechanism. To address this heterogeneity, we engineered T cells to express an anti-B7-H3 CAR and secrete an EGFR-targeting bispecific T-cell engager (EGFR-BsTe). These B7-H3-CAR-T-EGFR-BsTe cells exerted dual functionality: direct B7-H3-dependent cytotoxicity and recruitment of unmodified T cells via secreted EGFR-BsTe to eliminate EGFR-expressing tumor cells. Notably, EGFR-BsTe secretion promoted CAR-T cell proliferation and effector differentiation. In orthotopic GBM xenograft models, including mixed tumors with heterogeneous antigen expression, B7-H3-CAR-T-EGFR-BsTe cells demonstrated superior antitumor activity and prolonged survival compared to conventional B7-H3 CAR-T cells. Quantitative analysis revealed that EGFR-BsTe secretion abrogated EGFR upregulation and enhanced B7-H3 downregulation in a target-dependent manner; however, efficacy was diminished when the CAR-Target (B7-H3) was absent on a substantial fraction of tumor cells. Our findings suggest that arming B7-H3 CAR-T cells with EGFR-targeting bispecific engagers represents a promising strategy to overcome antigen heterogeneity and improve therapeutic outcomes for GBM patients. - Source: PubMed
Publication date: 2026/06/16
Zhang ZongliangYang NianZeng HuiChen YongdongLu HuaqingXu LongWang ZengWang GuoqingZhou LiangxueTong Aiping - Rhabdoid tumors (RT) are among the most aggressive pediatric malignancies, characterized by early onset in life, loss of SWI/SNF complex members (SMARCB1 or SMARCA4), and dismal outcomes despite multimodal therapy. Refractory and relapsing RT remain almost uniformly fatal, and targeted or immune-based approaches have yet to demonstrate clinical benefit. - Source: PubMed
Publication date: 2026/06/02
Reitsam Nic GFincke Victoria EHernandez Ramirez Maria DanielaMucha MarlenaSipos EvaLisa SiebenhüterEnke Johanna SLossner MauriceVokuhl ChristianLapa ConstantinHasselblatt MartinFrühwald MichaelMärkl BrunoJohann Pascal D - Diffuse intrinsic pontine glioma (DIPG) is a rare pediatric brain tumor with a critical unmet need due to the lack of approved, curative interventions available. The interweaving of malignant cells with normal tissue makes surgical extraction essentially impossible, and radiation provides only transient benefit. The recent ONC201 FDA approval, however, suggests DIPG therapy is tractable. Having identified overexpression of IL13Rα2 in DIPG tumor tissue versus normal brain tissue, we investigated binding of commercially available IL13Rα2 monoclonal antibodies. The top candidate antibody was used to generate a chimeric antibody, to which we conjugated deruxtecan to create a preclinical therapeutic candidate. - Source: PubMed
Publication date: 2026/05/19
Lian XiaoleiAllanson Victoria JRasmussen Samuel VChauhan ShefaliTan Guak-KimMorrow PaigeHanson KyleLian Emily BingHaight Anthony RHoshino TyujiLiu XianzhiBerlow Noah EKeller CharlesLian Yajun